
    
      Predictive factors to be considered are: histology, Heng risk group, Eastern Cooperative
      Oncology Group-performance status (ECOG-PS), site of metastases, glycemia and
      cholesterolemia.

      The data collected in this "real life" population could contribute to identify clinical
      factors that predict favourable outcomes in patients treated with everolimus after failure or
      a a first-line treatment with a VEGF inhibitor.
    
  